Nothing Special   »   [go: up one dir, main page]

WO1995025282A1 - Reactifs de capture d'ions et procedes de realisation de procedes de dosage par fixation - Google Patents

Reactifs de capture d'ions et procedes de realisation de procedes de dosage par fixation Download PDF

Info

Publication number
WO1995025282A1
WO1995025282A1 PCT/US1995/003168 US9503168W WO9525282A1 WO 1995025282 A1 WO1995025282 A1 WO 1995025282A1 US 9503168 W US9503168 W US 9503168W WO 9525282 A1 WO9525282 A1 WO 9525282A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid phase
reagent
analyte
capture reagent
capture
Prior art date
Application number
PCT/US1995/003168
Other languages
English (en)
Inventor
Robert G. Hiltibran
Yi-Her Jou
Stephen D. Stroupe
Steven J. Kline
Steven G. Schultz
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to AU19978/95A priority Critical patent/AU1997895A/en
Publication of WO1995025282A1 publication Critical patent/WO1995025282A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials

Definitions

  • This invention relates generally to the field of binding assay devices and methods.
  • the present invention relates to novel methods and products useful in the performance of immunoassays.
  • analytes can include antibodies, antigens, drugs, and hormones.
  • Immunoassay techniques take advantage of the mechanisms of the immune systems of higher organisms, wherein antibodies are produced in response to the presence of antigens which are pathogenic or foreign to the organisms. These antibodies and antigens, i.e.. immunoreactants, are capable of binding with one another, thereby causing a highly specific reaction mechanism which can be used in vitro to determine the presence or concentration of that particular antigen in a biological sample.
  • the "sandwich" or "two-site” technique may involve the formation of a ternary complex between an an f ._ gen and two antibodies.
  • a convenient method of detecting complex formation in such a technique is to provide one labeled antibody and an unlabeled antibody bound to a solid phase support such that the complex can readily be isolated.
  • the amount of labeled antibody associated with the solid phase is directly proportional to the amount of analyte in the test sample.
  • an alternative technique is the "competitive" assay.
  • the capture mechanism again may use an antibody attached to an insoluble solid phase, but a labeled analyte (rather than a labeled antibody) competes with the analyte present in the test sample for binding to the immobilized antibody.
  • a labeled analyte (rather than a labeled antibody) competes with the analyte present in the test sample for binding to the immobilized antibody.
  • an immobilized analyte can compete with the analyte of interest for a labeled antibody.
  • the quantity of captured labeled reagent is inversely proportional to the amount of analyte present in the sample.
  • the heterogeneous reaction mixture of soluble and insoluble reagents, and liquid test sample can retard the kinetics of the reaction.
  • the heterogeneous reaction mixture can require longer incubation periods for equilibrium to be reached in the reaction mixture between the insoluble solid phase system, the free analyte in the test sample, the soluble labeled reagent, and the newly formed insoluble complex.
  • binding members can produce a solid phase which will readily bind substances other than the analyte. This is referred to as nonspecific binding and can interfere with the detection of a positive result.
  • immobilization methods separate batches of manufactured solid phase reagents can contain variable amounts of immobilized binding member.
  • the present invention provides novel capture reagents to facilitate the observation of a detectable signal by separating the analyte and/or indicator reagent from the other assay reagents or test sample.
  • the capture reagents can comprise one or more anionic molecules attached to a specific binding member.
  • the present invention also involves activated polymeric anionic molecules; a method for modifying terminal amino groups on polymeric anionic molecules; and a method for detecting an analyte in a test sample.
  • a readily adapted anionic molecule is an activated polymeric anionic molecule having the formula:
  • X can represent a specific binding member which has been activated to bind the polymeric anionic molecule. Activation methods are also described by which one or more reactive groups are formed upon the specific binding member or the polymeric anion.
  • the specific binding member component of the capture reagent can be either a hapten or a acromolecule.
  • the charged capture reagent enables homogeneous assay and separation reactions wherein reaction complexes, as well as unreacted capture reagent, can be removed from the reaction mixture by contacting the mixture with an oppositely charged solid phase.
  • Virtually any binding assay can be adapted to use the novel capture reagents.
  • the present invention brings two advantages to binding assays: (a) the use of liquid phase kinetics in the binding reaction facilitates the formation of a complex from the homogeneous mixture of analyte and assay reagents, and (b) it increases the potential number of complexes that can be immobilized on the solid support.
  • the invention can also be used in a separation procedure wherein the capture reagent is conjugated to a charged substance.
  • a liquid sample suspected of containing the analyte to be separated is mixed with the capture reagent in solution to form a charged complex.
  • the solution is contacted to an oppositely charged solid phase to attract, attach, and separate the newly formed complex and unreacted capture reagent from the liquid sample.
  • the present invention also provides an efficient method of immobilizing binding members on a solid phase through ionic interaction between oppositely charged molecules.
  • DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
  • the assay methods and reagents of the present invention can be used in a variety of assay formats.
  • the present invention is not limited to immunoreactive assays. Any assays using specific binding reactions between the analyte and assay reagents can be performed. Definitions
  • specific binding member refers to a member of a specific binding pair, i.e.. two different molecules where one of the molecules through chemical or physical means specifically binds to the second molecule.
  • other specific binding pairs include biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence) , complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and the like.
  • specific binding pairs can include members that are analogs of the original specific binding member.
  • a derivative or fragment of the analyte i.e.. an analyte-analog
  • Immunoreactive specific binding members include antigens, haptens, antibodies, and complexes thereof including those formed by recombinant DNA methods or peptide synthesis.
  • An antibody can be a monoclonal or polyclonal antibody, a recombinant protein or a mixture (s) or fragment (s) thereof, as well as a mixture of an antibody and other specific binding members. The details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art.
  • hapten refers to a partial antigen or non-protein binding member which is capable of binding to an antibody, but which is not capable of eliciting antibody formation unless coupled to a carrier protein.
  • test sample refers to virtually any liquid sample.
  • the test sample can be derived from any desired source, such as a physiological fluid, for example, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, amniotic fluid or the like.
  • the liquid test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous liquids, or the like; methods of treatment can also involve separation, filtration, distillation, concentration, inactivation of interfering components, and the addition of reagents.
  • physiological fluids other liquid samples such as water, food products and the like can be used.
  • a solid can be used once it is modified to form a liquid medium.
  • analyte is the substance to be detected in or separated from the test sample using the present invention.
  • the analyte can be any substance for which there exists a naturally occurring specific binding member or for which a specific binding member can be prepared. In addition, the analyte may bind to more than one specific binding member.
  • "Analyte” also includes any antigenic substances, haptens, antibodies, and combinations thereof.
  • the analyte can include a protein, a peptide, an amino acid, a hormone, a steroid', a vitamin, a drug including those administered for therapeutic purposes as well as those administered for illicit purposes, a bacterium, a virus, and metabolites of or antibodies to any of the above substances.
  • analyte-analog refers to a substance which cross-reacts with an analyte-specific binding member, although it may do so to a greater or lesser extent than does the analyte itself.
  • the analyte-analog can include a modified analyte as well as a fragmented or synthetic portion of the analyte molecule so long as the analyte-analog has at least one epitopic site in common with the analyte of interest.
  • label refers to any substance which is attached to a specific binding member and which is capable of producing a signal that is detectable by visual or instrumental means.
  • suitable labels for use in the present invention can include chromogens; catalysts; fluorescent compounds; chemiluminescent compounds; radioactive labels; direct visual labels including colloidal metallic and non-metallic particles, dye particles, enzymes or substrates, or organic polymer latex particles; liposomes or other vesicles containing signal producing substances; and the like.
  • an enzyme/substrate signal producing system useful in the present invention is the enzyme alkaline phosphatase and the substrate nitro blue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate, or derivative or analog thereof, or the substrate 4- methylumbelliferyl-phosphate.
  • the label in an alternative signal producing system, can be a fluorescent compound where no enzymatic manipulation of the label is required to produce a detectable signal.
  • Fluorescent molecules such as fluorescein, phycobiliprotein, rhodamine and their derivatives and analogs are suitable for use as labels in this reaction.
  • a visually detectable, colored particle can be used as the label component of the indicator reagent, thereby providing for a direct colored readout of the presence or concentration of the analyte in the sample without the need for further signal producing reagents.
  • Materials for use as the colored particles are colloidal metals, such as gold, and dye particles as disclosed in U.S. Patent Nos. 4,313,734 and 4,373,932.
  • the preparation and use of non-metallic colloids, such as colloidal selenium particles, are disclosed in U.S. Patent No. 4,954,452.
  • the use of colloidal particle labels in immunochromatography is disclosed in U.S. Patent No. 5,120,643.
  • Organic polymer latex particles for use as labels are disclosed in co-owned and copending U.S. Patent Application Serial No. 07/248,858 filed September 23, 1988.
  • a “signal producing component,” as used herein, refers to any substance capable of reacting with another assay reagent or the analyte to produce a reaction product or signal that indicates the presence of the analyte and that is detectable by visual or instrumental means.
  • “Signal production system, " as used herein, refers to the group of assay reagents that are needed to produce the desired reaction product or signal.
  • one or more signal producing components can be used to react with a label and generate the detectable signal, i.e.. when the label is an enzyme, amplification of the detectable signal is obtained by reacting the enzyme with one or more substrates or additional enzymes to produce a detectable reaction product.
  • an “indicator reagent,” as used herein, refers to a label attached to a specific binding member.
  • the indicator reagent produces a detectable signal at a level relative to the amount of an analyte in the test sample.
  • the indicator reagent is detected or measured after it is captured on the solid phase material, but the unbound indicator reagent can also be measured to determine the result of an assay.
  • the specific binding member of the indicator reagent is capable of binding either to the analyte as in a sandwich assay, to the capture reagent as in a competitive assay, or to an ancillary specific binding member as in an indirect assay.
  • the label as described above, enables the indicator reagent to produce a detectable signal that is related to the amount of analyte in the test sample.
  • the specific binding member component of the indicator reagent enables the indirect binding of the label to the analyte, to an ancillary specific binding member or to the capture reagent.
  • a particular label is not critical, but the label will be capable of generating a detectable signal either by itself, such as a visually detectable signal generated by colored organic polymer latex particles, or in conjunction with one or more additional signal producing components, such as an enzyme/substrate signal producing system.
  • additional signal producing components such as an enzyme/substrate signal producing system.
  • indicator reagents can be formed by varying either the label or the specific binding member; it will be appreciated by one skilled in the art that the choice involves consideration of the analyte to be detected and the desired means of detection.
  • a “capture reagent,” as used herein, refers to an unlabeled specific binding member attached to a charged substance.
  • the attachment of the components is essentially irreversible and can include covalent mechanisms.
  • the capture reagent is used to facilitate the observation of the detectable signal by substantially separating the analyte and/or the indicator reagent from other assay reagents and the remaining test sample.
  • the specific binding member can be a small molecule, such as a hapten or small peptide, so long as the attachment to the charged substance does not interfere with the binding member's binding site.
  • the specific binding member of the capture reagent is -specific either for the analyte as in a sandwich assay, for the indicator reagent or analyte as in a competitive assay, or for an ancillary specific binding member, which itself is specific for the analyte, as in an indirect assay.
  • the charged substance can include anionic and cationic substances.
  • the charged substances may be monomeric or polymeric. In a preferred embodiment, the charged substance is a linear anionic polymer.
  • anionic polymers include polyglutamic acid (PGA) , anionic protein or derivatized protein such as albumin, anionic polysaccharides such as heparin or alginic acid, polyaspartic acid, polyacrylic acid, and polyamino acids having a net negative charge at an appropriate pH (such as a pH in the range of 4 to 10) .
  • Anionic polymers having a molecular weight of about 5000 to about 500,000 daltons are preferred.
  • the specific binding member can be joined to more than one charged monomer or polymer to increase the net charge associated with the capture reagent.
  • the attachment of the charged substance to the specific binding member typically does not result in either intermolecular or intramolecular crosslinking which causes an obstacle in conducting the claimed assay methods.
  • Coupling reagents which mediate the attachment of the charged substance and specific binding member by condensation of specific functional groups can be used.
  • commercially available (from SIGMA Chemical Co.) carbodiimide compounds such as N,N' -dicyclohexylcarbodiimide, and l-ethyl-3- (3- dimethylamino-propyl) carbodiimide can be employed.
  • these carbodiimide compounds conjugate antibody and polyglutamic acid (PGA) by condensing the amino-groups on antibody and carboxylic acid residues on PGA to form amide linkages.
  • PGA polyglutamic acid
  • the binding affinity of the charged substance to the oppositely charged solid phase should be higher than that of the binding member, analyte, indicator reagent and other materials present in the assay reaction mixture.
  • Assay protocols (such as one step and two step) , sample pretreatment, and assay sensitivity and range requirements may vary from analyte to analyte, and it will be appreciated by those skilled in the art that the selection of charged substance for the capture reagent in a given assay will be determined empirically.
  • Another technique that can be employed to avoid or reduce crosslinking is selecting a charged substance and a method of attaching it to the binding member so that there is a single covalent link between the charged substance and the specific binding member. This selection is within the skill in the art and can be made without undue experimentation. If the charged substance is a polyanion, crosslinking may also be avoided or reduced by selecting a polyanion which does not contain multiple activated groups.
  • conjugating polymeric anions to binding members are described in detail immediately below.
  • a negatively charged capture reagent can be prepared by conjugating a specific binding member to one or more activated polymeric anionic molecules and conjugate bases thereof represented by the general formula:
  • X can be an amine-reactive group or moiety, a thiol-reactive group or moiety, or a thiol group or moiety represented by -A-SH wherein A is a spacer arm.
  • a specific binding member having an amino group can be conjugated to an activated PGA anionic molecule having an amine-reactive moiety.
  • the amine-reactive moieties enable the binding of the activated polymer to an amino group on a specific binding member and include, but are not limited to, those represented by the following formulas:
  • R' is a sulfur stabilizer and R" is an aliphatic or aryl group.
  • Sulfur stabilizers include, but are- not limited to, 2-pyridyl, 4-pyridyl and 5-nitro-2-pyridyl groups.
  • A represents a spacer of about one to about thirty atoms including, but not limited to, carbon, nitrogen, sulfur and oxygen atom chains and combinations thereof such as polyether, polymethylene and polyamide, as well as aromatic spacers such as phenylene.
  • a specific binding member having a thiol group can be conjugated to an activated polymer having a thiol-reactive moiety.
  • the thiol-reactive moieties include, but are not limited to, those represented by the following formulas:
  • A is a spacer of about one to about thirty atoms as described above.
  • a specific binding member having a thiol-reactive group can be linked to an activated polymer having a thiol moiety such as -A-SH.
  • the negatively charged capture reagents of some of the following Examples were formed by reacting the desired specific binding member with an activated PGA molecule having modified terminal amino groups.
  • the modification method involved: (1) dissolving the PGA in a solvent (e. ⁇ .. a water miscible aprotic solvent such as dioxane, dimethylformamide, l-methyl-2-pyrrolidinone and dimethyl sulfoxide) ; (2) adding a proton absorbing reagent (e, ⁇ .. 4- methyl morpholine) in the amount of about one equivalent per titratable carboxylic acid; (3) adding about a 2 to about a 100 molar excess of an amine-reactive modification reagent (e. ⁇ ..).
  • a solvent e. ⁇ .. a water miscible aprotic solvent such as dioxane, dimethylformamide, l-methyl-2-pyrrolidinone and dimethyl sulfoxide
  • a proton absorbing reagent e, ⁇ .
  • Suitable proton absorbing reagents include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide or lithium hydroxide, and tertiary amines such as 4-methyl morpholine and triethylamine.
  • the polymeric anionic molecule or the specific binding member will include one or more amino, carboxyl or thiol groups or can be activated by the incorporation of an amino, carboxyl or thiol group thereby enabling the chemical linking of the specific binding member with the polymeric anionic molecule.
  • Activated species refer to specific binding members and polymeric anionic molecules which contain a reactive group through the incorporation of a linking or other activating agent.
  • the amine-reactive modification reagents are a subclass of those reagents used to "activate" a specific binding member or polymeric anionic molecule, i.e.. to prepare the specific binding member or the polymeric anionic molecule for chemical linking.
  • Activating agents also include thiol introducing agents such as the thiolanes (such as 2-iminothiolane) , succinimidyl mercaptoacetates (such as N- succinimydl-S-acetylmercaptoacetate) , and disulfide compounds which are subsequently reduced to a thiol.
  • thiol introducing agents such as the thiolanes (such as 2-iminothiolane) , succinimidyl mercaptoacetates (such as N- succinimydl-S-acetylmercaptoacetate) , and disulfide compounds which are subsequently reduced to a thiol.
  • the thiol introducing agents can be used to activate specific binding members for subsequent reaction with a thiol-reactive group.
  • Amine-reactive modification reagents include, but are not limited to, bifunctional linking or coupling agents, such as succinic anhydride analogs, iminothiolane analogs, homobifunctional reagents and heterobifunctional reagents, which enable the chemical linking of the specific binding member and the polymeric anionic molecule.
  • bifunctional linking or coupling agents such as succinic anhydride analogs, iminothiolane analogs, homobifunctional reagents and heterobifunctional reagents, which enable the chemical linking of the specific binding member and the polymeric anionic molecule.
  • homobifunctional reagents can be represented by the formula X- A-X wherein X is an amine-reactive group and A is a spacer of about one to about thirty atoms.
  • heterobifunctional reagents can be represented by the formula X-A-Y wherein X is an amine-reactive group, Y is a thiol- reactive moiety, a thiol moiety or a thiol precursor and A is a spacer of about one to about thirty atoms as described above.
  • Proteinaceous specific binding members with cysteine residues at the protein's active site can have their activity decreased by the addition of a coupling agent, therefore the cysteine residues in the active site must be protected, by means known in the art, prior to reacting the protein with the coupling agent.
  • the term "coupling agent, " as used herein, includes bifunctional linking or coupling agents, i.e..
  • the reactive ends can be any of a variety of functionalities including, but not limited to: amino reacting ends such as N-hydroxysuccinimide (NHS) active esters, imidoesters, aldehydes, epoxides, sulfonyl halides, isocyanate, isothiocyanate, and nitroaryl halides; and thiol reacting ends such as pyridyl disulfides, maleimides, thiophthalimides, and active halogens.
  • the heterobifunctional linking reagents have two different reactive ends, e.g..
  • homobifunctional reagents have two similar reactive ends, e.g.. -bismaleimidohexane (BMH) which permits the cross-linking of sulfhydryl-containing compounds, and NHS homobifunctional crosslinkers such as disuccinimidyl suberate (DSS) as well as the water soluble analogs, sulfo-NHS esters (Pierce 1989 Handbook and General Catalog; Pierce Chemicals, Rockford, IL, 61105-9976) .
  • BMH bismaleimidohexane
  • NHS homobifunctional crosslinkers such as disuccinimidyl suberate (DSS) as well as the water soluble analogs, sulfo-NHS esters (Pierce 1989 Handbook and General Catalog; Pierce Chemicals, Rockford, IL, 61105-9976) .
  • homobifunctional linking reagents include, but are not limited to, the imidoesters such as dimethyl adipimidate dihydrochloride (DMA) ; dimethyl pimelimidate dihydrochloride (DMP) ; and dimethyl suberimidate dihydrochloride (DMS) .
  • DMA dimethyl adipimidate dihydrochloride
  • DMP dimethyl pimelimidate dihydrochloride
  • DMS dimethyl suberimidate dihydrochloride
  • the iminothiolane analogs can be represented by the general formula:
  • A is a spacer of about 1 to about 5 atoms, e.g.. 2- iminothiolane (Traut's Reagent) .
  • heterobifunctional reagents suitable for use in the present invention include, but are not limited to, maleimido-NHS active esters coupling agents such as m-maleimidobenzoyl-N-hydroxy-succinimide ester (MBS); succinimidyl 4- (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC); succinimidyl 4- (p-maleimidophenyl)butyrate (SMPB) and derivatives thereof, including sulfosuccinimidyl derivatives such as sulfosuccinimidyl 4- (N-maleimido-methyl) cyclohexane- 1-carboxylate (sulfo-SMCC) ; m-maleimidobenzoyl- sulfosuccinimide ester (sulfo-MBS) and sulfosuccinimidyl 4-(p- maleimidophenyl)butyrate (
  • heterobifunctional reagents include commercially available active halogen-NHS active esters coupling agents such as N-succinimidyl bromoacetate and N- succinimi ⁇ yl (4-iodacetyl) -aminobenzoate (SIAB) and the sulfosuccinimidyl derivatives such as sulfosuccinimidyl (4- iodoacetyl) -aminobenzoate (sulfo-SIAB) .
  • Another group of coupling agents is the heterobifunctional and thiol cleavable agents such as N-succinimidyl 3- (2-pyridyldithio) -propionate (SPDP) .
  • coupling agents includes the extended length heterobifunctional coupling agents described in U.S. Patent Nos. 5,002,883 and 4,994,385 which are incorporated by reference herein.
  • the extended length heterobifunctional coupling agents include maleimido-NHS active ester reagents wherein the spacer is represented by the formula:
  • amir .. acid is a substituted or unsubstituted amino acid, having from three to ten carbon atoms in a straight chain; n is from one to ten; and R is an alkyl, cycloalkyl, alkyl-cycloalkyl or an aromatic carboxylic ring.
  • alkyl-cycloalkyl includes alkyl groups linked to cycloalkyl ring structures where the alkyl group links the cycloalkyl to a maleimide or carbonyl group.
  • alkyl includes straight or branched alkyl groups, preferably lower alkyl groups having from one to six carbon atoms.
  • the spacer can be any molecular chain that is non-reactive, stable and non-binding to the analyte or other specific binding members with which it will be used.
  • the length of the spacer can be varied and can range from the size of a single atom to the sizes disclosed in U.S. Patent Nos. 5,002,883 and 4,994,385 or larger.
  • amine-reactive modification reagent thiol introducing agent or other activating agent
  • suitable or preferred agents for use with the particular polymeric anionic molecule and specific binding member to be used in the diagnostic assay. Therefore, it will be appreciated by those skilled in the art that the coupling agent or activating agent used in a given assay will generally be determined empirically.
  • Suitable thiol-reactive moieties of the heterobifunctional reagents include, but are not limited to, those represented by the following formulas:
  • Suitable thiol precursor moieties include, but are not limited to, those represented by the following formulas:
  • Suitable amine-reactive moieties include, but are not limited to, those represented by the following formulas:
  • R' is a sulfur stabilizer, as described above, and R" is an aliphatic or aryl group.
  • a specific binding member having an amine-reactive group can be conjugated to a terminal amino group of the polymeric anionic molecule.
  • a conjugation procedure involves: (1) dissolving PGA in a solvent (e.g. , a water miscible aprotic solvent such as dioxane, dimethylformamide, l-methyl-2- pyrrolidinone and dimethyl sulfoxide) ; (2) adding a proton absorbing reagent (e.g..
  • an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, or lithium hydroxide, or a tertiary amine such as -methyl morpholine or triethylamine
  • amine-reactive specific binding member e.g.. phosgene-activated phenylcyclidine or phenylcyclidine- 4-chloroformate
  • A is a spacer of about one to about thirty atoms as described above, m is two or three, R' is a sulfur stabilizer and R" is an aliphatic or aryl group.
  • An example of the preparation of a negatively charged capture reagent involves the reaction of a specific binding member (SBM) having an amino group and an activated PGA having an amine-reactive moiety.
  • SBM specific binding member
  • PGA activated PGA having an amine-reactive moiety
  • an "ancillary specific binding member, " as used herein, refers to any member of a specific binding pair which is used in the assay in addition to the specific binding members of the capture reagent and the indicator reagent.
  • an ancillary specific binding member may bind the analyte as well as a second specific binding member to which the analyte itself could not attach, or as in an inhibition assay the ancillary specific binding member may be a reference binding me'iber as described below.
  • One or more ancillary specific bindi - g members can be used in an assay.
  • solid phase refers to any material which is insoluble, or can be made insoluble by a subsequent reaction.
  • the solid phase can be chosen for its intrinsic charge and ability to attract the capture reagent, e.g.. methylated wool, nylons, and special glasses having a positive charge.
  • the solid phase can include any suitable porous material.
  • porous is meant that the material is one through which liquids can flow and can easily pass.
  • the solid phase can include a fiberglass, cellulose, or nylon pad for use in a pour and flow-through assay device having one or more layers containing one or more of the assay reagents; a dipstick for a dip and read assay; a test strip for wicking (e.g. , paper) or thin layer chromatographic (e.g.. nitrocellulose) techniques; or other porous material well known to those skilled in the art.
  • the solid phase is not limited to porous materials.
  • the solid phase can also comprise polymeric or glass beads, microparticles, tubes, sheets, plates, slides, wells, tapes, test tubes, or the like, or any other material which has an intrinsic charge or which can retain a charged substance.
  • Natural, synthetic, or naturally occurring materials that are synthetically modified can be used as a solid phase including polysaccharides, e.g., cellulose materials such as paper and cellulose derivatives such as cellulose acetate and nitrocellulose; silica; inorganic materials such as deactivated alumina, diatomaceous earth, MgS04, or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g.. cotton) and synthetic (e.g.
  • polysaccharides e.g., cellulose materials such as paper and cellulose derivatives such as cellulose acetate and nitrocellulose
  • silica silica
  • inorganic materials such as deactivated alumina, diatomaceous earth, MgS04, or other inorganic finely divided material uniformly dispersed in a porous poly
  • solid phase materials include a porous fiberglass material, such as a "Whatman 934-AH" filter paper, which has a nominal thickness of 0.33 mm, or the disposable IMXTM wedge and TESTPACKTM (fiber matrix) devices of Abbott Laboratories (Abbott Park, IL) .
  • the thickness of such material is not critical, and will be a matter of choice, largely based upon the properties of the sample or analyte being assayed, such as the fluidity of the test sample.
  • a charged substance can be coated directly to the material or onto microparticles which are then retained by a solid phase support material.
  • microparticles alone can be used as the charged solid phase.
  • Particles can serve as the solid phase, by being retained in a column or being suspended in the mixture of soluble reagents and test sample, or the particles themselves can be retained and immobilized by a solid phase support material.
  • retained and immobilized is meant that the particles on or in the support material are not capable of substantial movement to positions elsewhere within the support material.
  • the particles can be selected by one skilled in the art from any suitable type of particulate material composed of polystyrene, polymethylacrylate, polypropylene, latex, polytetrafluoroethylene, polyacrylonitrile, polycarbonate, or similar materials.
  • a charged substance is retained on the solid phase so that there is a relatively uniform charge distributed throughout the solid phase.
  • the solid phase should retain a charged substance that is at least equally and oppositely charged with respect to the charged substance of the capture reagent.
  • an anionic substance can be bound to the capture reagent, and a cationic substance can be retained on the solid phase, or vice versa.
  • Natural, synthetic, or naturally occurring materials that are synthetically modified, can be used as the cationic substance.
  • a cationic substance is retained on the solid phase.
  • the cationic substance is a polymeric substance. Even more preferably, the cationic polymer is a linear polymer.
  • the polymeric substance may be a homopolymer or a copolymer, and preferably, has a relatively high molecular weight, for instance, above about 100,000 daltons. It is also preferable that the polymeric cation substance has little, if any, binding affinity for the indicator reagent employed in the assay. Selection of suitable cationic substances is most critical for assays requiring high sensitivity and extensive washings of the solid phase (such as in two step assays) .
  • the polymeric cationic substance is a quaternary ammonium compound.
  • the invention contemplates that a variety of quaternary ammonium compounds may be employed. Quaternary ammonium compounds having about 1% to about 10% nitrogen (exclusive of counter ion) in the form of quaternary ammonium moiety are preferred. Examples of linear quaternary ammonium polymeric compounds that may be employed include but are not limited to, commercially available compounds known as MERQUAT®, CELQUAT®, GAFQUAT®, and MAGNIFLOC®.
  • MERQUAT® is commercially available from Calgon, Pittsburgh, PA.
  • the MERQUAT® compound is a homopolymer of dimethyldiallylammonium chloride and has a nitrogen content of about 8.75%.
  • MERQUAT® has a molecular weight of about 10 s to about l ⁇ 6 daltons, and has about one positive charge per 161 dalton.
  • the structure of MERQUAT® is shown below:
  • n 620-6200
  • CELQUAT® is commercially available from National Starch & Chemical Corporation, Bridgewater, NJ.
  • CELQUAT® is a copolymer of hydroxyethylcellulose and dimethyldiallylammonium chloride. it has a molecular weight of about IO 5 dalton and has a nitrogen content of about 1% to 2%. The compound has about one positive charge per 700 - 1400 dalton.
  • GAFQUAT® is commercially available from GAF Corporation, Wayne, NJ. It is the reaction product of diethyl sulfate and a copolymer of vinylpyrrolidone and dimethylaminoethylmethacrylate. The compound has a molecular weight of about IO 5 to about 10 6 dalton.
  • the chemical structure of GAFQUAT® is shown below:
  • MAGNIFLOC® is commercially available from C YTEC Industries, Indianapolis, IN. The compound is a copolymer of dime hylamine and epichlorohydrin and has a nitrogen content of about 10.2%. M A G N IFLOC® has about one positive charge per 137 dalton. T he structure of MAGNIFLOC® is shown below:
  • n 1500-2200
  • polymeric cation substances include but are not limited to hexadimethrine bromide (POLYBRENE®) and diethylaminoethyl- dextran, both available from Sigma Chemical Company, St.
  • MER Q UAT® or MAGNIFLOC® is retained on the solid phase. Applicants have found that these polymeric cationic substances provide increased capturing efficiency for polyanionic charged capture reagent, particularly PGA charged capture reagent.
  • the anionic and cationic substances may be selected on the basis of charge density. If quaternary ammonium compounds such as MERQUAT® are utilized for coating the solid phase, selection of the polyanion substance is also made in view of the analyte being assayed. Typically, the total charge of the solid phase should be at least equal to the total charge of the charged capture reagent in the reaction mixture. It is preferred, however, to have greater total positive charge on the solid phase as compared to the total charged polyanion in the capture reagent. Applicants have found that an optimal amount of MERQUAT® employed in an assay is stoichiometrically about 50 to about 150 times in excess the amount of polyanion charged capture reagent. Methods for retaining the cationic charged substance on the solid phase are known in the art, and are described in detail in the Examples below.
  • nonspecific binding is typically not a problem using the presently disclosed ion- capture techniques.
  • prevention of nonspecific binding may be accomplished in several ways.
  • the anionic and cationic substances may be selected so that they are the dominant charges in the reaction mixture.
  • polyanion/polycation binding consists of high binding affinities due to the extended linear conformation of the polyanion and polycation (in contrast to most protein molecules which are in globular form) and the cooperative nature of the binding shown by the multiple pairing of oppositely charged groups on the polymers.
  • Nonspecific binding can also be reduced or avoided by including a nonspecific binding blocker in the indicator reagent.
  • a nonspecific binding blocker such as dextran sulfate or carboxymethyl cellulose
  • the nonspecific binding blocker could be a free polyanion even when the capture reagent used in the assay involved a polyanionic substance conjugated to a specific binding member. It would have been expected that the presence of a free or unbound polyanion would prevent, or at least reduce, the immobilization of the capture reagent on the solid phase.
  • nonspecific blocker was more effective in inhibiting the direct, nonspecific binding of indicator reagent to the solid phase than it was in reducing the attachment of the polyanionic capture reagent to the polycationic solid phase.
  • Suitable nonspecific binding blockers include, but are not limited to, dextran sulfate, heparin, carboxymethyl dextran, carboxymethyl cellulose, pentosan polysulfate, inositol hexasulfate and ⁇ -cyclodextrin sulfate. Nonspecific binding blockers and their use in the disclosed assays is further described in Examples 14 and 15 below.
  • the amount of polyanionic nonspecific binding blocker added to the indicator reagent can be greater than the amount of polyanionic substance contained in the capture reagent. It was found that free polyanionic nonspecific binding blocker could be added to the indicator reagent in amounts 40,000 times the amount of polyanionic substance used in the capture reagent. Generally, the preferred amount of polyanionic blocker added to the indicator reagent is 50 to 14,000 times the amount of polyanionic substance used in the capture reagent. For two step sandwich assays, the preferred amount of polyanionic blocker added to the indicator reagent is 1000 to 2000 times that contained in the capture reagent.
  • an appropriate range of use of the nonspecific binding blocker can be determined for each analyte of interest. For example, in an assay to detect thyroid stimulating hormone (TSH) wherein dextran sulfate was added to the indicator reagent as a free polyanionic nonspecific binding blocker, suitable amounts of free polyanion ranged from 233 to 19,000 times that of the capture reagent, or about 0.1-8% dextran sulfate. As illustrated in Examples 15, 16, and 17, the preferred nonspecific binding blocker as well as the preferred amount of nonspecific binding blocker can be optimized for each analyte of interest and each assay format.
  • TSH thyroid stimulating hormone
  • the preferred nonspecific binding blocker is selected by empirical techniques which can be performed without undue experimentation by one of ordinary skill in the art.
  • a sandwich assay can be performed wherein a soluble capture reagent can include an analyte-specific binding member which has been bound to a charged substance such as an anionic substance.
  • the ionic species can be a monomer or a polymer.
  • the capture reagent is contacted with a test sample, suspected of containing the analyte, and an indicator reagent comprising a labeled analyte-specific binding member.
  • the reagents can be mixed simultaneously or added sequentially, either singly or in combination. For instance, in a one step assay, the capture reagent and indicator reagent are mixed simultaneously with the test sample.
  • the capture reagent is mixed with the test sample and the indicator reagent is subsequently contacted with the reaction mixture.
  • a binding reaction results in the formation of a capture reagent/analyte/indicator reagent complex.
  • the assay also comprises the step of separating the resultant complexes from the reaction mixture by using a solid phase that is either oppositely charged with respect to the capture reagent or that retains an oppositely charged substance, for example a cationic substance.
  • the oppositely charged solid phase attracts and attaches capture reagent/analyte/indicator reagent complexes, as well as unreacted capture reagent, through the ionic interaction of the anionic and cationic substances.
  • the complexes, if any, retained on the solid phase are then detected by examining the solid phase for the indicator reagent. If analyte is present in the sample, then label will be bound to the solid phase material. The amount of label on the solid phase is proportional to the amount of analyte in the sample.
  • the only major limitation inherent in the sandwich assay is the requirement for the analyte to have a sufficient size and appropriately orientated epitopes to permit binding of at least two specific binding members.
  • the present invention also can be used to conduct a competitive assay.
  • the soluble capture reagent again includes a specific binding member which has been attached to a charged substance, such as an anionic polymer.
  • the capture reagent is contacted with both test sample and an indicator reagent that includes a second binding member which has been labeled with a signal generating compound.
  • the assay can be performed as a one step assay or two step assay, as described above. Either the capture reagent and analyte can compete in binding to the indicator reagent (e.g..).
  • the capture reagent and analyte are antigens competing for a labeled antibody) , or the indicator reagent and analyte can compete in binding to the capture reagent (e.g.. the indicator reagent is a labeled antigen which competes with the antigen analyte for binding to the antibody capture reagent) .
  • a competitive binding reaction occurs resulting in the formation of soluble complexes of (1) capture reagent/analyte or indicator reagent/analyte and (2) capture reagent/indicator reagent.
  • the soluble capture reagent/analyte complexes, capture reagent/indicator reagent complexes and/or unreacted capture reagent are removed from the reaction mixture by contacting the reaction mixture with the oppositely charged solid phase, for example, a cationic substance on a solid phase.
  • the complexes and unreacted capture reagent are retained on the solid phase through the ionic interaction of the opposite charges.
  • the complexes retained on the solid phase can be detected via the label of the indicator reagent.
  • the amount of label that becomes bound to the solid phase is inversely proportional to the amount of analyte in the sample. Thus, a positive test sample will generate a negative signal.
  • the competitive assay is advantageously used to determine the presence of small molecule analytes, such as small peptides or haptens, which have a single epitope with which to bind a specific binding partner.
  • an anti- theophylline antibody (either monoclonal or polyclonal) can be conjugated with an anionic substance to form a soluble capture reagent, and a competition for binding to that antibody can be established between the soluble labeled theophylline (i.e.. indicator reagent) and the unlabeled theophylline of the test sample.
  • the homogeneous reaction mixture can be contacted to a cation-coated solid phase.
  • the ionic interaction between the oppositely charged ionic species of the capture reagent and the solid phase separates the formed complexes and unreacted capture reagent from the reaction mixture.
  • the signal from the indicator reagent can then be detected.
  • increased theophylline levels in the test sample will result in decreased label bound to the solid phase.
  • the present invention can also be used in indirect immunoassays using one or more ancillary specific binding members.
  • an indirect sandwich immunoassay with the formation of a capture reagent/analyte/anti-analyte antibody/indicator reagent complex can be performed, wherein the indicator reagent is a specific binding partner for the ancillary specific binding member which is specific for the analyte.
  • the capture reagent may include a specific binding partner for the ancillary specific binding member which is specific for the analyte.
  • the present invention can be used in an inhibition assay, such as the measurement of an antibody by inhibiting the detection of a reference antigen.
  • the capture reagent can include an antibody/anion conjugate and the indicator reagent can be a labeled antibody.
  • the test sample, suspected of containing an antibody analyte is mixed with a reference antigen with which the capture reagent and indicator reagent can form a detectable sandwich complex that can be immobilized upon a solid phase.
  • the degree of inhibition of antigen uptake by the capture reagent is proportional to the amount of antibody analyte in the test sample, thus, as the concentration of the antibody analyte increases, the less reference antigen is available to complete the immobilized sandwich complex.
  • the solid phase is used as a separation mechanism; the homogeneous reaction mixture is contacted with the solid phase, and the newly formed complexes, and unreacted capture reagent, are retained on the solid phase through the ionic interaction of the opposite charges of the solid phase and the capture reagent. If the user is not concerned with liquid phase kinetics, the capture reagent can be pre-immobilized on the solid phase to form a "capture situs," i.e.. that region of the solid phase having one or more capture reagents non- diffusively attached thereto.
  • the present invention can also be used for separating a substance from a liquid sample.
  • the capture reagent and solid phase can be used without an indicator reagent for the sole purpose of separating an analyte from a test sample.
  • the capture reagent can be contacted with a soluble second charged substance which is oppositely charged with respect to the capture reagent. The second charged substance is not retained on the solid phase prior to contacting the sample to the solid phase material, but it attracts and attaches to the capture reagent such that the resultant assay complexes are retained on the solid phase.
  • analyte When the complex of charged capture reagent and analyte (and/or indicator reagent), and any unreacted capture reagent, is contacted to the oppositely charged solid phase, the ionic attraction of the oppositely charged anion and cation species governs the efficiency of the separation of the complexes and unreacted capture reagent from the reaction mixture.
  • analyte may be determined or quantitated without further processing steps such as centrifugation or filtration.
  • the ionic interaction of the anionic and cationic substances can be selected to provide a greater attraction than the immunological attraction of antibody for antigen, particularly when multiple polycationic and polyanionic species are included in the capture reagent and solid phase.
  • a further advantage is that the "ion-capture" technique minimizes the nonspecific adsorption of interfering substances onto the solid phase, thereby offering improved accuracy of analysis.
  • the ion-capture technique thereby enables the performance of an assay having a highly specific separation method, minimal nonspecific binding, and high sensitivity.
  • Example 1 illustrate preferred ways of making the novel materials of the present invention and performing assay procedures using those materials.
  • the Examples are intended only to be illustrative, and are not to be construed as placing limitations upon the scope of the invention, which scope is defined solely by the appended claims.
  • the PDP-PGA was dissolved in 0.1 M Na phosphate and 1 mM EDTA (pH 6.5) and stirred with thiopropyl SEPHAROSE® 6B (60 ml; 30 grams; Pharmacia Chemicals, Uppsala, Sweden) . After dialysis and lyophilization, a 24% yield of the PDP-PGA conjugate was obtained (0.244 grams; 1.72 x IO -5 mole) .
  • thiopyridyl group was exchanged for a 5-thio-2-nitrobenzoate (TNB) protecting group.
  • TAB 5-thio-2-nitrobenzoate
  • a 100 mole excess of 1, 4-dithiothreitol (MW 154.2) was added to a solution of the PDP-PGA (20 mg; 1.42 x 10 ⁇ 6 mole) dissolved in 0.1 M sodium phosphate (4.0 ml; pH 7), and the reaction was run for one hour at 40°C.
  • the mixture was diluted to ten milliliters with 5.0 mM sodium acetate, 0.14 M NaCl, and 1.0 mM EDTA (pH 5.5) and dialyzed in 2000 molecular weight cut off (MWCO) tubing against the dilution buffer. Dialysis was continued against distilled water, followed by lyophilization.
  • Antibody activation The monoclonal antibody, an anti-CEA antibody was maleimide activated per the method of Tuskada et al. (JNCI: 73; 721-729, 1984) with the following exceptions.
  • the antibody concentration was one mg/ml, and a 150 mole excess of N-succinimidyl m-(N-maleimido) benzoate (SMBE, MW 314.3; Sigma) was used. It was determined experimentally that a 150 mole excess was necessary to introduce between three and five maleimide groups to the anti- CEA antibody. Clean-up was performed using the Meares et al.
  • the thiopropyl-fluorescein-labeled PGA was then reacted with the maleimide derived antibody to yield the antibody/PGA conjugate appropriate for a carcinoembryonic antigen ion-capture immunoassay.
  • the maleimide-activated antibody (1.0 mg; 6.25 x IO" 9 mole) in 0.1 M sodium phosphate (1.0 to 2.0 ml; pH 7.0) was pH adjusted to 6.5 with 1.0 N HCl.
  • a 10 mole excess of HS-PGA/EDA-FI approximately 1.0 mg
  • 0.1 M sodium phosphate 100 ⁇ l
  • the mixture was diluted to ten milliliters in 0.1 M sodium phosphate (pH 7.0) and dialyzed in 50,000 MWCO tubing against 0.001 M Na phosphate (pH 7.0) followed by lyophilization.
  • the dry material was redissolved in distilled water (0.25 ml) and high performance liquid chromatography (HPLC) fractionated for the largest peak at A280.
  • HPLC high performance liquid chromatography
  • the chromatography was performed using a Bio-Sil TSK250 (Bio-Rad Laboratories, Richmond, California) 300 mm x 7.5 mm column, eluted at one milliliter/minute with 50 mM sodium sulfate, 20 mM sodium phosphate, and 0.3 M NaCl (pH 6.8) .
  • the largest peak was assayed for protein content using Bio-Rad's Bradford assay with a bovine IgG standard.
  • the peak contained 95.5 ⁇ g/ml protein equating to 5.97 x IO" 7 molar protein (IgG MW 160,000).
  • This fraction also contained 2.12 x 10 ⁇ 6 molar fluorescein.
  • the equation of the molar fluorescein gave 3.6 fluoresceins per antibody molecule. Knowing that there were 0.81 fluoresceins per PGA molecule, this equated to 4.4 PGA molecules conjugated to each antibody.
  • the peak fraction was frozen and subsequently used in the assay.
  • a cationic derived antibody could also be formed for use in conjunction with an anionic solid phase material.
  • the solid phase fibrous matrix of a disposable IMXTM (Abbott Laboratories) wedge was coated with a polymeric quaternary compound to give the solid phase a positive charge.
  • CELQUAT® L-200 a water soluble cellulose derivative, was used.
  • a 1% aqueous solution of CELQUAT® L-200 (50 ⁇ l) was applied to the solid phase material, followed by a wash of diluent containing 300 mM NaCl, 50 mM Tris and 0.1% NaN3 (75 ⁇ l; pH 7.5) .
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and anti-CEA antibody fragment, which binds to a different epitope than the antibody specified in the capture reagent.
  • the alkaline phosphatase-labeled anti-CEA antibody fragment was in a buffer containing: 50 mM Tris, 50 mM NaCl, 1.0 mM MgCl2, 0.1 mM ZnCl2, 5.0 mM sodium tartrate,
  • a protein-A affinity purified mouse monoclonal immunoglobulin G was coupled to negatively charged PGA using a water-soluble carbodiimide reagent (l-ethyl-3- (3- dimethylamino-propyl) carbodiimide; EDCI) according to the following procedures .
  • a water-soluble carbodiimide reagent l-ethyl-3- (3- dimethylamino-propyl) carbodiimide; EDCI
  • Fluorescein-labeled PGA (10 mg; FI-PGA) was added to an ice-cold solution of the antibody (4.8 mg/ml) in phosphate- buffered saline (PBS; 75 mM KH2PO and 300 mM NaCl at pH 7.2).
  • PBS phosphate- buffered saline
  • a porous fibrous matrix material was coated with a polymeric quaternary ammonium compound (GAFQUAT® 755N; GAF Corporation) to form the solid phase.
  • GAFQUAT® 755N polymeric quaternary ammonium compound
  • An aqueous solution of 0.5% GAFQUAT® 755N (50 ⁇ l) was applied to the surface of the material, followed by a water wash (75 ⁇ l) .
  • the indicator reagent an alkaline phosphatase conjugate of sheep anti-mouse immunoglobulin (Jackson ImmunoResearch Laboratories, Inc.; West Grove, PA 19390), was diluted in Tris-buffered saline containing 1% fish gelatin [25 mM Tris (hydroxymethyl) aminomethane and 100 mM NaCl, pH 7.5].
  • the capture reagent of PGA/mouse monoclonal antibody conjugate (Pool I of Table 2) was similarly treated. Two hundred microliters of each reagent was added to a series of test tubes which were then incubated at 37°C for 30 minutes.
  • the initial concentration of PGA-coupled antibody before mixing with alkaline phosphatase-labeled sheep anti-mouse immunoglobulin was five ⁇ g/ml.
  • the indicator reagent titer is the reciprocal of the dilution of the reagent stock. d. Enhancement of Antigen/Antibody Complex Binding to Solid Phase
  • Capture reagent (pool I) was prepared as described in Section (a) above.
  • the amounts of MIgG were serially diluted to 10, 1, 0.1, and 0.01 microgram/ml, respectively.
  • the solid phase was prepared as described in Section (b) above except that porous fibrous matrix material without the coating of GAFQUAT® 755N was used for the NO QUAT controls.
  • the capture reagent and indicator reagent were reacted under the conditions described in Section (c) above. The results are shown in Table 3(a) below.
  • MIgG MIgG-PGA MIgG-PGA MIgG MIgG ( ⁇ g/ml) QUAT NO QUAT NO PGA NO PGA QUAT NO QUAT
  • the low signals in columns 3 and 4 demonstrate that there was virtually no binding of indicator reagent (alkaline phosphatase-sheep an i-MIgG) on the solid phase. Formation of MIgG/indicator complexes when the MIgG was not conjugated to the polyanion was not sufficient to specifically bind the complexes to the cation coated solid phase, thus, resulting in a very low specific signal.
  • the marginal increase of signals in column 2 compared to columns 3 and 4 shows that even the tremendously increased amount of negative charge (from the PGA) attached to the complexes was still insufficient to facilitate the binding of the complexes to the solid phase when the solid phase was not coated with the polycationic QUAT compound.
  • the capture reagent and indicator reagent were prepared as described above. All of the reagents were diluted in Tris-buffered saline containing 1% fish gelatin. The indicator reagent was diluted 1000-fold from the stock solution, and the capture reagent was diluted to 10 ⁇ g/ml. In a series of test tubes, 150 ⁇ l each of appropriately diluted indicator reagent, capture reagent, and mouse monoclonal antibody were mixed. The mixtures were incubated at 37°C for 30 minutes. Aliquots of the mixtures (75 ⁇ l) were applied to the quat-treated solid phase materials, immediately followed by three 150 ⁇ l washes of Tris-buffered saline.
  • results of this example illustrating a competitive inhibition assay for mouse IgG are shown in Table 5.
  • the results demonstrate that as the mouse monoclonal antibody concentration increased there was a corresponding decrease in the formation of capture reagent/indicator reagent complex, and therefore, the amount of detectable label bound to the solid phase decreased.
  • Indicator Reagent Alkaline Phosphatase- Sheep Anti-Mouse Immunoglobulin Conjugate
  • a highly negatively charged albumin derivative was prepared and coupled to anti-hCG antibodies to form the capture reagent according to the following procedures. Modification of rabbit serum albumin to form a negatively charged protein derivative: Rabbit serum albumin (RSA) was extensively succinylated and coupled with para- azobenzenesulfonate by the procedure of Jou et al. , (Methods in Enzymology: Vol. 92, Part E; 257-276, Academic Press, 1983) . Two percent RSA in phosphate-buffered saline (PBS, 14 ml, pH 8.0) was mixed with 5% succinic anhydride in para- dioxane (2.28 ml) .
  • PBS phosphate-buffered saline
  • Anti-hCG F(ab')2 fragments were prepared according to the method of Nisonoff et al. (Arch. Biochem. Biophy. : 89; 230-244, 1960) from affinity purified goat anti-hCG antibodies. A portion of affinity purified -antibody solution in phosphate buffered saline (pH 7.2) was acidified to pH 4 by adding acetic acid. The preferred concentration of antibodies at this point was one mg/ml. Pepsin was added to reach a final concentration of 20 ⁇ g/ml. The mixture was incubated at 37°C overnight. The reaction was stopped by adding 6.0 N NaOH to bring the reaction mixture to a pH of 7.5.
  • the digested antibody fragments solution was concentrated to 20 mg/ml.
  • the F(ab')2 fragments were purified by gel-filtration high performance liquid chromatography using a Spherogel T ⁇ K-3000SWG column (2.15 cm x 30 cm) fitted with a Spherogel TSK-G guard column (2.15 cm x 7.5 cm) .
  • Anti- hCG Fab' fragments were prepared and derivatized into a thiol- reactive form according to a modification of the methods of Parham et al. (J. Immunol. Method. : 53:133-173, 1982) and Brennan et al. (Science: 229: 81-83, 1985) . With stirring, a solution (158 ⁇ l) of 0.1 M NaAs ⁇ 2 containing 20 M EDTA was added to 1.28 ml of goat F(ab')2 (goat anti-human chorionic gonadotropin antibody fragment, 16 mg/ml) containing trace 125 -F(ab')2 i- n PBS.
  • the reductive cleavage reaction was started by adding 0.1 M cystein-HCl (158 ⁇ l) .
  • the reaction mixture was overlayed with nitrogen and incubated with stirring at 37°C for one hour.
  • the reaction was then quenched by adding 19 mg of 5, 5 ' -dithiobis- (2-nitrobenzoic acid) .
  • RSA a solution of 1 M dithiothreitol (DTT; 86 ⁇ l) was added to a solution (4.2 ml) containing Sp-SUCg5-RSA (2.2 mg/ml) in 37.5 mM sodium phosphate, 150 mM NaCl, and 2.0 mM EDTA (pH 6.8). The mixture was incubated at 37°C for three hours and then at room temperature overnight. The resulting reaction mixture was chromatographed on a 2.5 cm x 20 cm column packed with SEPHADEX® G-25 (Pharmacia Inc.) and preequilibrated with 75 mM sodium phosphate, 300 mM NaCl, and 2.0 mM EDTA (pH 6.8) . A 2ml portion of the pooled fractions of reduced SP-SUC55-RSA
  • RSA a solution (27 ⁇ l) of 30 mM succinimidyl 4- (N-maleimido- methyl) -cyclohexane-1-carboxylate in N,N-dimethylformamide was added to 2.25 ml of affinity purified goat arti-hCG antibody (3 mg/ml) in PBS. The resulting reaction mixture was stirred for one hour at room temperature and then chromatographed on a PD-10 column preequilibrated with 75 mM sodium phosphate, 300 mM NaCl, and 2.0 mM EDTA (pH 6.8) . A 1.8 ml portion of the pooled fractions of modified antibodies (1.6 mg/ml) was mixed with 3ml of the DTT-reduced Sp-SUCg5 ⁇ RSA (0.48 mg/ml) .
  • the antibody Sp- SUCgs-RSA conjugate was purified by size exclusion high performance liquid chromatography in the manner described above.
  • the indicator reagent consisted of an alkaline phosphatase-goat anti-hCG antibody conjugate (prepared by coupling anti-hCG antibody to periodate activated alkaline phosphatase) in an assay buffer containing 25 mM Tris (hydroxymethyl) aminomethane, 100 mM NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 0.07% NaN3, and 1% fish gelatin at pH 7.5.
  • the ion-capture immunoassay protocol included the use of a solid phase prepared substantially in accordance with the method described in Example 2, the indicator reagent (alkaline phosphatase-goat anti-hCG antibody conjugate), one of two different capture reagents (goat anti-hCG Fab'-Sp- SUCg 5 -RSA and goat anti-hCG IgG-Sp-SUCg5-RSA) as prepared in
  • Example 3.a above, and a purified hCG standard solution. All reagents were appropriately diluted (as determined by a titer curve) in the assay buffer. Equal volumes (750 ⁇ l) of the indicator reagent and hCG sample solution were placed in a series of test tubes. After incubation at 37°C for 30 minutes, a 125 ⁇ l aliquot of each incubated mixture was mixed in a separate tube with an equal volume of a capture reagent. The resulting mixtures were incubated for 30 minutes. The assay mixture (75 ⁇ l) was then added to each solid phase material.
  • the solid phase materials were then washed three times with 150 ⁇ l amounts of washing buffer [25 mM Tris (hydroxymethyl) aminomethane, 100 mM NaCl, 1.0 mM MgCl2, 0.1 mM ZnCl2, and 0.07% NaN3 at pH 7.5].
  • An enzyme substrate 70 ⁇ l of 1.2 mM 4-methylumbelliferylphosphate in a solution of 100 mM AMP, 1.0 mM MgCl2, 0.1% NaN3, and 4.0 mM tetramisole at pH 10.3 was then added to the solid phase materials. The resulting rate of fluorescence was measured at 32.7°C. The results of the experiment are summarized in Table 6.
  • Indicator Reagent hCG-Specific Goat igG-Alkaline Phosphatase
  • hCG-Specific Capture Reagents hCG ( mIU/r nl Goat IgG-Sp- ⁇ UC 65 -R ⁇ A Goat Fab' -Sp-SUCg ⁇ -RSA
  • the indirect ion-capture immunoassay included the use of a solid phase prepared substantially as described in Example 2 above, an indicator reagent of alkaline phosphatase- sheet anti-mouse IgG conjugate (Jackson immunoResearch Laboratories, Inc.), a capture reagent of goat anti-hCG Fab'- Sp-SUCg5 ⁇ RSA as prepared in Example 3, an ancillary specific binding member of mouse monoclonal anti-hCG antibodies (ImmunoSearch; Thomas River, NJ 08753), and a purified hCG standard solution. The ancillary specific binding member was used to bind with the analyte and the indicator reagent. All reagents were appropriately diluted in the assay buffer.
  • Indicator Reagent Sheep Anti-Mouse IgG-Alkaline Phosphatase
  • the ion-capture immunoassay protocol included the case of a solid phase prepared substantially in accordance with the method described in Example 2, an indicator reagent of alkaline phosphatase-sheep anti-mouse IgG conjugate (Jackson ImmunoResearch Laboratories, Inc.), an ancillary specific binding member of mouse monoclonal anti-hCG antibodies (ImmunoSearch; Thomas River, NJ 08753), and a purified hCG standard solution. Additionally, the protocol used a second ancillary specific binding member of affinity purified goat anti-hCG antibodies and a capture reagent of rabbit anti-goat IgG-Sp-SUCg5 ⁇ RSA.
  • the capture reagent was prepared by coupling affinity purified rabbit anti-goat IgG (Cappel; Cochranville, PA 19330) to Sp-SUCg5 ⁇ RSA according to the procedure described in Example 3 above. All reagents were appropriately diluted in the assay buffer. Equal volumes (100 ⁇ l) of the indicator reagent, hCG sample solution, and first ancillary specific binding member were placed in a series of test tubes. After incubation (37°C for ten minutes) the second ancillary specific binding member (100 ⁇ l) was added and the incubation was continued (at 37°C for an additional five minutes) . Finally, capture reagent (100 ⁇ l) was added to each tube. The resulting mixtures were incubated for five minutes.
  • Indicator Reagent Sheep Anti-Mouse IgG-Alkaline Phosphatase
  • Ancillary Specific Binding Member Mouse Monoclonal Anti-hCG Antibody
  • ITC-PGA isothiocyanate-PGA
  • the ITC-PGA (295 ⁇ g; 2.5 x 10 ⁇ 8 mole; in 40 ⁇ l of 20% DMF/0.1 M sodium phosphate at pH 7.0) was added to a buffered solution of goat anti-mouse IgG (200 ⁇ g; 1.25 x 10 ⁇ 9 mole; Sigma Chemical Company; in 40 ⁇ l of 0.1 M sodium phosphate at pH 7) to form the PGA- abeled goat anti-mouse capture reagent. After stirring at room temperature for two days, 0.1 M Tris (20 ⁇ l; pH 7.4) was added and the resulting mixture was stored at 2 to 8°C until used.
  • the anti-progesterone antibody ion-capture immunoassay included the use of solid phase materials coated with a polymeric quaternary compound as described in Example 1.
  • a 60 ⁇ l sample was added to a reaction well.
  • the samples consisted of a monoclonal anti-progesterone antibody at concentrations of 0, 5, 50, 100, 250, and 500 ng/ml in phosphate-buffered saline (PBS, 50 mM sodium phosphate, 99 mM NaCl, 0.1% NaN3, at pH 7.4)
  • PBS phosphate-buffered saline
  • 20 ⁇ l of PBS were added to the reaction well, followed by 20 ⁇ l of the buffered indicator reagent, progesterone labeled with alkaline phosphatase (3 ⁇ g/ml in a Tris buffer of 50 mM Tris, pH 7.4, 150 mM NaCl, 1% aN3 # 1 mM MgCl2, 0.1 mM
  • the capture reagent was added (20 ⁇ l; PGA-labeled goat anti-mouse antibody at a 1/100 dilution in PBS of the stock solution described above) .
  • the mixture was then incubated an additional ten minutes at 34.5°C.
  • a 100 ⁇ l aliquot of the mixture was then applied to the solid phase material, followed by three 75 ⁇ l washes of diluent.
  • the enzyme substrate solution (70 ⁇ l; 1.2 mM 4-methylumbelliferyl-phosphate in a solution of 100 mM AMP, 1 mM MgCl2, 0.1% NaN3 , and 4.0 mM tetramisole at pH 10.3) was added to the solid phase, and the resulting rate of fluorescence was measured.
  • the results of the assay are shown in Table 9. The results demonstrate that as the anti- progesterone antibody test sample concentration increased there was a corresponding increase in the formation of capture reagent/analyte/indicator reagent complex, and therefore, the amount of detectable label bound to the solid phase increased.
  • the solid phase was prepared substantially in accordance with the method described in Example 1.
  • a 60 ⁇ l sample of various concentrations of progesterone in PBS was mixed with 20 ⁇ l of progesterone-labeled alkaline phosphatase indicator reagent (0.4 ⁇ g/ml in the Tris buffer of Example 4) and 20 ⁇ l of mouse anti-progesterone antibody as an ancillary specific binding member (0.3 ⁇ g/ml in PBS) .
  • 20 ⁇ l of the PGA- labeled goat anti-mouse antibody capture reagent were added as described in Example 6 above.
  • the resulting mixture was incubated an additional ten minutes at 34.5°C.
  • Ancillary Specific Binding Member Mouse Anti-Progesterone Antibody
  • the sodium salt of PGA (100 mg; 7.35 x 10 ⁇ 6 mole; average MW 13,600; Sigma) was stirred overnight with a hydrogen form cation exchange resin (50 equivalents/glutamate residue; AG50W-X8; Bio-Rad) .
  • the resin previously had been swelled and washed in distilled water, and finally resuspended in distilled water (20 ml/7 gms dry weight of beads) .
  • the supernatent was removed and lyophilized providing a 90% yield of the free acid form of PGA (PGAFA) as a white powder (80 mg; average MW 11,620) .
  • the free acid form was used to obtain solubility in organic solvents.
  • the PGAFA was dissolved in solvent (DMF at ten milligrams/milliliter) .
  • a proton absorbing reagent (4-methyl morpholine) was added to the solution in the amount of about one equivalent per titratable free carboxylic acid.
  • an amine-reactive modification reagent (1, 4-phenylene diisothiocyanate [DITC] in sufficient DMF to dissolve it) was added to the solution.
  • DITC 4-phenylene diisothiocyanate
  • the ITC-PGAFA (at about a 1 to about a 20 mole excess to the protein) was dissolved in 0.2 M sodium phosphate buffer at pH 8.5 with the volume held as low as possible. The pH was adjusted to 8.5 as necessary. The desired protein was added to this solution and incubated overnight at 37°C. The preparations were then fractionated using HPLC on either an analytical TSK 400 Bio-Rad column (7.5 x 300 mm, at a 1 ml/min flow rate) for 1-2 milligram protein preparations, or a TSK 4000 Beckman column (31.5 x 300 mm, at a 5 ml/min flow rate) for 2-10 milligram protein preparations.
  • the elution buffer contained 0.1 M sodium phosphate and 0.3 M NaCl at pH 6.8. Fractions were tested and appropriately combined. The amino acid content was determined for those fractions containing protein so that the coupling efficiency for the various proteins at various coupling ratios could be determined. The results of the determinations are presented in Table 11.
  • Anti-CEA antibody 1 0.77 monoclonal 1.0 mg 5 1.7
  • Anti- ⁇ hCG antibody 10 4.6 monoclonal 1.0 mg 15 5.2 monoclonal 10 mg 15 7.8
  • Column 1 of Table 11 lists the quantity of protein used in the reactions to form the various capture reagents.
  • Column 2 lists the mole excess of activated ITC-PGAFA that was reacted with the Column 1 protein.
  • Column 3 provides the number of PGA chains attached per antibody by the reaction, calculated by amino acid analysis based upon a 40,000 average MW and 305 repeating glutamate residues.
  • Theophylline Ion-Capture Competitive Assay-Antigen Capture Format a. Preparation Of Theophylline Capture Reagent
  • the activation of theophylline was accomplished by dissolving theophylline-butylate (10 mg; MW 280.29; 3.57 x 10" 5 moles) in methylene chloride (3.0 ml) . A three mole excess of dicyclohexyl-carbodiimide (22 mg; MW 206.3) and a three mole excess of N-hydroxysuccinimide (12.3 mg; MW 115.09) were added, and the reaction mixture was stirred over night at room temperature.
  • the mixture was filtered to remove dicyclohexylurea and was rotavaporated to dryness to yield ten milligrams of N-succinimidyl-theophylline-butylate (theophylline-butylate-oSu) .
  • the theophylline-PGA capture reagent which was capable of binding with anti- theophylline antibody, was then diluted to 3 ⁇ g/ml in an assay buffer containing 25 mM Tris, 100 mM NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 0.1% NaN 3 , and 1% fish gelatin at pH 7.2.
  • a fiber matrix was coated with a polymeric quaternary compound to provide the solid phase with a positive charge.
  • CELQUAT® L-200 a water soluble cellulose derivative, was used.
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and anti-theophylline antibody, made substantially in accordance with the protocol described in Example 3.b.
  • the indicator reagent was appropriately diluted ( as determined by titer curve) in the assay buffer to give 0.17 micrograms of antibody/milliliter.
  • the indicator reagent (200 ⁇ l) was placed within a series of reaction tubes.
  • a theophylline standard solution ( 200 ⁇ l; theophylline-butylate diluted to 0.6, 1.2, 2.3, 4.9, 9.9, 99.2, and 992 ⁇ g/ml in 50 mM Tris, 300 mM NaCl and 0.1% N N3 at pH 7.2) was then added to each tube. The mixture was incubated ten minutes at 37°C. Capture reagent (200 ⁇ l) was added to each tube, and the reaction mixtures were incubated ten minutes at 37°C.
  • Indicator Reagent Alkaline Phosphatase- Labeled Anti-Theophylline Antibody
  • Theophylline (ng/ml) Rate Of Fluorescence (counts/sec/sec)
  • Phenylcyclidine Ion-Capture Competitive Assav-Antigen Capture Format a. Preparation Of Phenylcyclidine Capture Reagent
  • the phenylcyclidine-4-chloroformate (1.1 mg) was dissolved in THF (0.5 ml). To this was added NH2-PGAFA (1.7 g; MW 11,798; 1.19 x 10 ⁇ 7 moles) dissolved in l-methyl-2- pyrrolidinone (0.5 ml). The reaction was carried out overnight at room temperature and then rotavaporated to dryness. The product was dissolved in 0.1 M sodium phosphate (1.5 ml, pH 7.0). The precipitate was filtered, and the cloudy aqueous filtrate was extracted with methylene chloride until clear. The phenylcyclidine-PGA capture reagent, which was capable of binding with anti-phenylcyclidine antibody, was then diluted to 5 ⁇ g/ml in an assay buffer as described in Example 9.
  • the solid phase was prepared substantially in accordance with the method described in Example 9.
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and anti-phenylcyclidine antibody.
  • the indicator reagent was diluted 1/250 in the assay buffer as described in Example 9.
  • the indicator reagent 140 ⁇ l was mixed with a series of samples (50 ⁇ l each) containing known amounts of phenylcyclidine (0.0, 25, 60, 120, 250 and 500 ng/ml prepared in human urine) , and the mixtures were incubated for ten minutes at 32°C.
  • the phenylcyclidine-PGA capture reagent 100 ⁇ l was added, and the reaction mixtures were incubated for ten minutes.
  • An aliquot of each reaction mixture 200 ⁇ l was applied to a solid phase material. The solid phase was then washed, two times.
  • An enzyme substrate 70 ⁇ l; as described in Example 9) was added, and the resulting rate of fluorescence was measured.
  • the results of the assay are shown in Table 13. The results demonstrate that as the phenylcyclidine test sample concentration increased there was a corresponding decrease in the formation of capture reagent/indicator reagent complex, and therefore, the amount of detectable label bound to the solid phase decreased.
  • Indicator Reagent Alkaline Phosphatase- Labeled Anti-Phenylcyclidine Antibody
  • Phenylcyclidine (ng/ml) Rate Of Fluorescence (counts/sec/sec)
  • the digoxin-IgG-PGA capture reagent was prepared substantially in accordance with the method described in Example 8.c, with the following procedural modifications.
  • the ITC-PGA (5 mg; 1.25 x IO" 7 mole; in 1.0 ml of 0.1 M sodium phosphate at pH 8.5) was added to a buffered solution of rabbit IgG-digoxin (1 mg; 6.25 x IO -9 mole; in 1.45 ml of 0.1 M sodium phosphate and 0.3 M NaCl at pH 8.5) to form the capture reagent.
  • the solution was stirred and incubated overnight at 37°C.
  • the preparation was then fractionated using HPLC on a BioSil 400 (Bio-Rad 300 mm x 7.5 mm gel filtration column) and eluted at one milliliter/minute with 0.1 M sodium phosphate and 0.3 M NaCl at pH 6.8.
  • the digoxin- IgG-PGA capture reagent which was capable of binding with anti-digoxin antibody, was then diluted to 3 ⁇ g/ml in an assay buffer as described in Example 9. /US95/03168
  • the solid phase was prepared substantially in accordance with the method described in Example 9.
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and mouse anti-digoxin antibody (immuno- search; Emeryville, California 94608) .
  • the indicator reagent was diluted to 33.3 ng/ml in the assay buffer as described in Example 9.
  • the indicator reagent (200 ⁇ l) was mixed with a series of samples (200 ⁇ l) containing known amounts of digoxin
  • Indicator Reagent Alkaline Phosphatase- Labeled Anti-Digoxin Antibody
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and digoxin (Immuno-search) .
  • the indicator reagent was diluted to 1/100 in the assay buffer as described in Example 9.
  • the anti-digoxin-PGA capture reagent (200 ⁇ l, prepared substantially in accordance with the protocol described in Example 8.c) was mixed with a series of samples (200 ⁇ l each) containing known amounts of digoxin as described in Example 11. The mixtures were incubated for 15 minutes at 37°C. The indicator reagent (200 ⁇ l) was added, and the reaction mixtures were incubated for 15 minutes. An aliquot of each reaction mixture (200 ⁇ l) was applied to the solid phase (prepared as described in Example 9), followed by a wash. An enzyme substrate (70 ⁇ l; as described in Example 9) was added, and the resulting rate of fluorescence was measured. The results of the assay are shown in Table 15. The results demonstrate that as the digoxin test sample concentration increased there was a corresponding decrease in the formation of capture reagent/indicator reagent complex, and therefore, the amount of detectable label bound to the solid phase decreased.
  • An anti-hCG antibody-PGA capture reagent was prepared substantially in accordance with the method described in Example 8.c. above.
  • a fiber matrix was wetted with buffer (80 ⁇ l; containing 300 mM NaCl, 50 mM Tris and 0.1% NaN3 at pH 7.5).
  • the indicator reagent consisted of a conjugate of alkaline phosphatase and goat anti-hCG antibody (made substantially in accordance with the protocol described in Example 3.b) .
  • the indicator reagent was appropriately diluted (as determined by titer curve) in assay buffer containing 25 mM Tris, 100 mM NaCl, 1 mM MgCl2 , 0.1 mM ZnCl2, 0.1% Na 3 , 5% goat serum and 1% fish gelatin at pH 7.2.
  • the indicator reagent 140 ⁇ l was mixed with a series of samples (50 ⁇ l) containing known amounts of hCG in normal human serum. The mixtures were incubatec for 10 minutes at 31-32°C. The anti-hCG antibody-PGA capture reagent (100 ⁇ l) was added, and the reaction mixtures were incubated for 10 minutes. An aliquot of each reaction mixture (200 ⁇ l) was applied to the solid phase material, followed by a wash. An enzyme substrate (70 ⁇ l; as described in Example 9) was added, and the resulting rate of fluorescence was measured. The results of the assay are shown in Table 16.
  • Indicator Reagent Alkaline Phosphatase-Labeled Anti-hCG Antibody
  • anti-hCG-PGA was independent of its complex formation with analyte (hCG) and indicator reagent (alkaline phosphatase-goat anti-hCG) .
  • indicator reagent alkaline phosphatase-goat anti-hCG
  • Test sample application pads (glass fiber matrix) were treated with various concentrations of an aqueous solution of MERQUAT®-100 polymeric ammonium compound, 100 mM Tris, 100 mM sodium chloride, 0.1% fish gelatin, 0.1% sucrose and 0.1% sodium azide. The application pads were allowed to dry, and the pads were overlaid upon a layer of absorbent material. Substantially the same procedure was used to prepare a flow-through solid phase device treated with CELQUAT® L-200 polymeric compound. Alternative devices were prepared by treating the application pad with MERQUAT® -100 polymeric quaternary ammonium compound (a cationic homopolymer of dimethyldiallylammonium chloride, 0.5% in water) immediately before use.
  • MERQUAT®-100 polymeric ammonium compound 100 mM Tris, 100 mM sodium chloride, 0.1% fish gelatin, 0.1% sucrose and 0.1% sodium azide.
  • the indicator reagent was a conjugate of goat anti- ⁇ -hCG antibody and alkaline phosphate, diluted in 1% Brij®-35 polyoxyethylene (23) lauryl ether (Sigma), 100 mM Tris, 500 mM NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 0.1% NaN3 and 0.5% non-fat dry milk at pH 7.2.
  • the indicator reagent was filtered through a 0.22 ⁇ m filter before use.
  • dextran sulfate MW 5,000
  • heparin was included as a nonspecific binding blocker.
  • the blocker was used to enhance the signal-to-noise ratio by inhibiting the binding of the labeled antibody to non-analyte.
  • a monoclonal anti- ⁇ -hCG antibody-PGA capture reagent was prepared substantially in accordance with the method described in Example 8.c. above. Every five milliliters of the coupling reaction mixture was fractionated on a gel filtration chromatography column (2.4 x 54 cm, at a 0.4 ml/minute flow rate) .
  • the elution buffer contained 0.1 M sodium phosphate, 0.3M NaCl and 0.05% NaN3 , at pH 8.5.
  • the polymeric anion/antibody conjugate was diluted with 25 mM Tris, 100 mM NaCl, 1 mM MgCl2> 0.1 mM ZnCl2, 0.1% NaN3 , 10% normal mouse serum and 1% fish gelatin at pH 7.2.
  • the capture reagent was filtered through a 0.22 ⁇ m filter before use. d. Immunoassay Protocol
  • the capture reagent (80 ⁇ l) was mixed with an equal volume of test sample containing a known amount of hCG in normal human serum. The mixture was incubated at approximately 31-32° for approximately twelve minutes. The specific binding reaction resulted in the formation of a capture reagent/analyte complex.
  • reaction mixture 80 ⁇ l was then applied to a flow-through device, followed by a wash with Tris buffered saline (75 ⁇ l) .
  • the indicator reagent 50 ⁇ l was then applied to the solid phase device and incubated for twelve minutes. The device was then washed two times.
  • the cationic homopolymer of dimethyldiallylammonium chloride was a preferred polymeric cation for the preparation of the solid phase for use in two- step assays wherein the device is subjected to one or more washings, e.g. the MERQUAT®-100 polymeric ammonium compound has a nitrogen content of about 8% (exclusive of counter ion)
  • the CELQUAT® H-100 polymeric compound has a nitrogen content of about 1% (exclusive of counter ion) .
  • Capture reagent anti- ⁇ -hCG antibody-PGA (0.5 ⁇ g/test)
  • Indicator reagent alkaline phosphatase-labeled anti- ⁇ -hCG antibody (with and without nonspecific binding blocker)
  • Solid phase coated with a cationic homopolymer of dimethyldiallylammonium chloride immediately before use
  • Rate of fluorescence counts/sec/sec
  • hCG mlU/m 2% dextran sulfate no blocker 0 68 255
  • Capture reagent anti- ⁇ -hCG antibody-PGA (0.5 ⁇ g/test)
  • Indicator reagent alkaline phosphatase-labeled anti- ⁇ -hCG antibody (with blocker)
  • Solid phase with varying cationic polymer concentration
  • Rate of fluorescence counts/sec/sec
  • MEROUAT®-100 polymeric ammonium compound %w/v
  • Capture reagent anti- ⁇ -hCG antibody-PGA
  • Indicator reagent alkaline phosphatase-labeled anti- ⁇ -hCG antibody
  • Rate of fluorescence counts/sec/sec
  • Quantity of capture antibody ll/test
  • Example 15 Ion-capture Flow-Through Device for Thyroid Stimulating
  • TSH Hormone
  • An application pad (glass fiber matrix) was treated with an aqueous solution of MERQUAT®-100 polymeric ammonium compound substantially in accordance with the procedure described in Example 14.a. The pad was then overlaid upon a layer of absorbent material to complete the flow-through solid phase device.
  • the indicator reagent was a conjugate of goat anti- ⁇ -hCG antibody and alkaline phosphatase, diluted in 1% Brij®- 35 polyoxyethylene (23) lauryl ether, 1% fish gelatin, 100 mM Tris, 500 mM NaCl, 1 mM MgCl2, 0.1% NaN 3 and 0.5% non-fat dry milk at pH 7.2.
  • the indicator reagent was filtered through a 0.22 ⁇ m filter before use. Dextran sulfate (0.5%,MW 5,000) was added as a nonspecific binding blocker. -73 -
  • the capture reagent was prepared by coupling a Protein A purified monoclonal anti-TSH antibody with carboxymethylamylose (CMA; Polysciences, Inc. , Warrington, PA) . Coupling was performed using a water-soluble carbodiimide reagent (l-ethyl-3- (3-dimethylaminopropyl) carbodiimide; EDCI) substantially in accordance with the following procedure.
  • CMA carboxymethylamylose
  • EDCI water-soluble carbodiimide reagent
  • the coupling mixture contained an antibody solution (2 ml; 1 mg/ml in MES buffer [25 nM,2-(N-)
  • the column was eluted with PBS (0.1 M sodium phosphate, 0.3 M NaCl and 0.05% sodium azide, at pH 6.8) .
  • the purified Antibody/CMA capture reagent was diluted in a diluent containing 50 mM Tris, 300 mM NaCl, 1% bovine serum albumin, 2.5% fish gelatin and 0.1% NaN3, at pH 7.5.
  • the capture reagent (30 ⁇ l) and Tris buffered saline (100 ⁇ l; 500 mM Tris, 300 mM NaCl and 0.1% NaH3) were mixed with a test sample (50 ⁇ l) containing a known amount of hCG in normal human serum.
  • the reaction mixture was incubated at approximately 33-34° for approximately ten minutes.
  • the specific binding reaction resulted in the formation of a capture reagent/analyte complex.
  • results of the assay are shown in Table 20.
  • Rate of fluorescence (counts/sec/sec)
  • Radioiodinated TSH was used in the assay protocol, as described in Example 15.d, to demonstrate the more efficient TSH capturing of CMA-coupled antibodies than that of polyaspartic- and polyglutamic-coupled antibodies.
  • the coupling of antibodies to the polyanions was performed substantially in accordance with the method described above (Example 15.c.) After the rate of fluorescence was measured at the end of the assay protocol, the radioactivity of TSH captured on the solid phase material was also measured by means of a gamma counter (Auto-Logic, Abbott Laboratories, North Chicago, IL) . The results of this procedure are demonstrated in Table 20 (a) .
  • a glass fiber matrix was treated with an aqueous solution of MERQUAT®-100 polymeric ammonium compound substantially in accordance with the procedure described in Example 14(a) above.
  • the pad was then overlaid upon a layer of absorbent material to complete the device.
  • the indicator reagent was a goat anti- ⁇ -hCG antibody conjugated to alkaline phosphatase and diluted in 3.33% Brij®- 35 polyoxyethylene (23) lauryl ether, 5 mM Tris, 1 mM MgCl2, 0.1 mM ZnCl 2 , 0.1% NaN3 and 5% fish gelatin at pH 7.2.
  • the indicator reagent was filtered through a 0.2 ⁇ rr filter before use.
  • carboxymethyl cellulose (MW 250,000) or carboxymethyl dextran was included as a nonspecific binding blocker.
  • a monoclonal anti-hCG antibody-PGA capture reagent was prepared substantially in accordance with the method described in Example 15(c) above.
  • the polymeric anion/antibody conjugate was diluted with 3.33% Brij®-35 polyoxyethylene (23) lauryl ether, 5 mM Tris, 500 mM NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 0.1% Na 3 , and 5% fish gelatin at pH
  • the enzyme substrate was 1.2 mM 4-methylumbelliferyl- phosphate in a solution of 100 mM AMP, 0.01% EDTA, 0.1% NaN3, and 4.0 mM tetramisole at pH 10.3
  • the capture reagent (50 ⁇ l) , indicator reagent (55 ⁇ l) and sample diluent buffer (35 ⁇ l; 75% normal calf serum, 25% normal goat serum and 0.2% NaN3, filtered through a 0.22 ⁇ m filter before use) were mixed with a test, sample (30 ⁇ l) containing a known amount of hCG in normal human serum. The mixture was incubated at approximately 33-34°C for approximately fourteen minutes. The specific binding reaction resulted in the formation of a capture reagent/analyte/indicator reagent complex.
  • results of the assay are shown in Table 21.
  • Indicator Reagent Alkaline Phosphatase-Labeled Anti-hCG Antibody
  • Rate of fluorescence (counts/sec/sec) % of carboxymethyl dextran in indicator rea ⁇ ent hCG (mlV/ml) Q. o.oi 0.25 £
  • Test sample application pads (glass fiber matrix) were treated with various concentrations of an aqueous solution of CELQUAT® L-200 polymeric quaternary ammonium compound or MERQUAT®-100 polymeric ammonium compound, 100 mM Tris, 100 mM sodium chloride, 0.1% fish gelatin, 0.1% sucrose and 0.1% sodium azide. The application pads were allowed to dry, and the pads were overlaid up:n a layer of absorbent material to form the individual assay devices.
  • the indicator reagent was a conjugate of T3 and alkaline phosphatase, diluted in 50 mM Tris, 100 mM NaCl, 1.0 mM MgCl2, 0.1 mM ZnCl2 and 1.0% bovine serum albumin at pH
  • Dextran sulfate (MW 5,000) was included as a nonspecific binding blocker.
  • the blocker was used to enhance the signal- to-noise ratio by inhibiting the binding of the labeled antibody to non-analyte.
  • the capture reagent an anti-T3 antibody coupled to polyaspartic acid (PAA-anti-T3 antibody) , polyacrylic acid (PAcA-anti-T3 antibody) or carboxymethyl cellulose (CMA-anti- T3 antibody) anionic polymer molecules, was prepared substantially in accordance with the method described in the Example 15(c) EDCI coupling method, with the exception that no chromatographic filtration of the capture reagent was performed.
  • the capture reagent was diluted with 800 mM Tris, 50 mM NaCl, 0.1% aN3, 0.01% furosemide, 0.1% Tween-20, 1.0% bovine serum albumin and 0.08 mg/ml goat IgG at pH 7.4. d. Immunoassay Protocol
  • the capture reagent 50 ⁇ l was mixed with an equal volume of test sample, containing a known amount of Total T3, and sample diluent buffer (150 ⁇ l) .
  • the reaction mixture was incubated for approximately 15 minutes. The specific binding reaction resulted in the formation of a capture reagent/analyte complex.
  • reaction mixture 150 ⁇ l was then applied to a solid phase.
  • the indicator reagent 60 ⁇ l was then applied to the solid phase and incubated for eight minutes. The device was then washed two times. An enzyme substrate (50 ⁇ l) was added, and the resulting rate of fluorescence was measured.
  • the solid phase was also washed prior to the addition of the indicator reagent.
  • the capture reagent and test sample were combined and incubated, followed by the addition of indicator reagent and further incubation prior to placing an aliquot of the reaction mixture on the solid phase.
  • the results demonstrated that as the Total T3 test sample concentration increased there was a corresponding increase in the formation of capture reagent/analyte complex, and therefore, the amount of detectable label bound to the solid phase decreased. Furthermore, the results show that the signal to noise ratio is improved by including a nonspecific binding blocker, dextran sulfate, in the indicator reagent.
  • EDAC-PAA anti-T3 EDAC-PAA anti-T3
  • Indicator Reagent No Blocker With 0.1% dextran sulfate

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne de nouveaux réactifs techniques de séparation et procédés de dosage permettant à la fois au réactif indicateur et au réactif de capture d'être en solution, de façon à éviter des problèmes posés par une cinétique de réaction ralentie. Le processus de séparation implique un réactif de capture soluble comprenant un élément de fixation spécifique fixé à une substance chargée et une phase solide insoluble présentant une charge contraire à celle de la substance chargée comprise dans le réactif de capture. Un spécimen de contrôle susceptible de contenir l'analyte concerné est mélangé avec le réactif de capture, de façon à obtenir un complexe analyte/réactif de capture chargé. Le mélange réactionnel est mis en contact avec la phase solide à charge opposée, afin d'attirer, de fixer er de séparer les complexes analyte/réactif de capture et tout réactif de capture n'ayant pas subi de réaction du mélange réactionnel. On peut réaliser à la fois des procédés de dosage sandwich et compétitifs au moyen d'un réactif indicateur approprié, à savoir un deuxième élément de fixation spécifique conjugué à un marquage pouvant émettre un signal détectable.
PCT/US1995/003168 1994-03-15 1995-03-14 Reactifs de capture d'ions et procedes de realisation de procedes de dosage par fixation WO1995025282A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19978/95A AU1997895A (en) 1994-03-15 1995-03-14 Ion-capture reagents and methods for performing binding assays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21401794A 1994-03-15 1994-03-15
US08/214,017 1994-03-15

Publications (1)

Publication Number Publication Date
WO1995025282A1 true WO1995025282A1 (fr) 1995-09-21

Family

ID=22797459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003168 WO1995025282A1 (fr) 1994-03-15 1995-03-14 Reactifs de capture d'ions et procedes de realisation de procedes de dosage par fixation

Country Status (2)

Country Link
AU (1) AU1997895A (fr)
WO (1) WO1995025282A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947324A1 (fr) * 1996-02-19 1999-10-06 MAXIMOVSKY, Sergei Nicolaevich Procede d'impression et dispositif d'impression permettant de mettre en oeuvre ce procede
EP2037272A1 (fr) * 2006-06-30 2009-03-18 Chisso Corporation Trousse de detection et de quantification d'analyte, et procede de detection et de quantification d'analyte
US8198073B2 (en) 2006-01-19 2012-06-12 Lattec I/S Dry stick device and method for determining an analyte in a sample
US8206944B2 (en) 2006-01-19 2012-06-26 Lattec I/S Dry stick device construction and method for determining an analyte in a sample using said dry stick device
US11437141B2 (en) 2009-04-30 2022-09-06 Dexcom, Inc. Performance reports associated with continuous sensor data from multiple analysis time periods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268296A2 (fr) * 1986-11-19 1988-05-25 Genetic Systems Corporation Essai immunologique de membrane-affinité-concentration
EP0326100A2 (fr) * 1988-01-29 1989-08-02 Abbott Laboratories Essais et dispositifs à capture d'ions
EP0406473A1 (fr) * 1989-07-07 1991-01-09 Abbott Laboratories Réactifs pour la capture d'ions et méthodes pour effectuer des dépistages de liaison
WO1992021769A1 (fr) * 1991-05-30 1992-12-10 Abbott Laboratories Reactifs contenant un inhibiteur de fixation non specifique pour analyses de fixation avec capture d'ions
WO1992021770A1 (fr) * 1991-05-30 1992-12-10 Abbott Laboratories Reactifs et procedes permettant de realiser des analyses de fixation avec capture d'ions en deux etapes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268296A2 (fr) * 1986-11-19 1988-05-25 Genetic Systems Corporation Essai immunologique de membrane-affinité-concentration
EP0326100A2 (fr) * 1988-01-29 1989-08-02 Abbott Laboratories Essais et dispositifs à capture d'ions
EP0406473A1 (fr) * 1989-07-07 1991-01-09 Abbott Laboratories Réactifs pour la capture d'ions et méthodes pour effectuer des dépistages de liaison
WO1992021769A1 (fr) * 1991-05-30 1992-12-10 Abbott Laboratories Reactifs contenant un inhibiteur de fixation non specifique pour analyses de fixation avec capture d'ions
WO1992021770A1 (fr) * 1991-05-30 1992-12-10 Abbott Laboratories Reactifs et procedes permettant de realiser des analyses de fixation avec capture d'ions en deux etapes

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947324A1 (fr) * 1996-02-19 1999-10-06 MAXIMOVSKY, Sergei Nicolaevich Procede d'impression et dispositif d'impression permettant de mettre en oeuvre ce procede
EP0947324A4 (fr) * 1996-02-19 2001-04-11 Sergei Nicolaevich Maximovsky Procede d'impression et dispositif d'impression permettant de mettre en oeuvre ce procede
US8198073B2 (en) 2006-01-19 2012-06-12 Lattec I/S Dry stick device and method for determining an analyte in a sample
US8206944B2 (en) 2006-01-19 2012-06-26 Lattec I/S Dry stick device construction and method for determining an analyte in a sample using said dry stick device
US8460863B2 (en) 2006-01-19 2013-06-11 Lattec I/S Dry stick device and method for determining an analyte in a sample
EP2037272A1 (fr) * 2006-06-30 2009-03-18 Chisso Corporation Trousse de detection et de quantification d'analyte, et procede de detection et de quantification d'analyte
EP2037272B1 (fr) * 2006-06-30 2013-09-18 JNC Corporation Trousse de detection et de quantification d'analyte, et procede de detection et de quantification d'analyte
US8815518B2 (en) 2006-06-30 2014-08-26 Jnc Corporation Kit for detection/quantification of analyte, and method for detection/quantification of analyte
US11437141B2 (en) 2009-04-30 2022-09-06 Dexcom, Inc. Performance reports associated with continuous sensor data from multiple analysis time periods

Also Published As

Publication number Publication date
AU1997895A (en) 1995-10-03

Similar Documents

Publication Publication Date Title
EP0406473B1 (fr) Réactifs pour la capture d'ions et méthodes pour effectuer des dépistages de liaison
US5670381A (en) Devices for performing ion-capture binding assays
JP3267613B2 (ja) イオン捕獲結合アッセイにおける非特異的結合遮断薬を含む試薬
US5459078A (en) Methods and reagents for performing ion-capture digoxin assays
EP0326100B1 (fr) Essais et dispositifs à capture d'ions
US5459080A (en) Ion-capture assays using a specific binding member conjugated to carboxymethylamylose
EP0586574B1 (fr) Procedes et reactifs avec capture d'ions permettant de determiner la teneur en digoxine
US5866322A (en) Method for performing Rubella assay
EP0586605B1 (fr) Reactifs et procedes permettant de realiser des analyses de fixation avec capture d'ions en deux etapes
EP0641442B1 (fr) Dispositifs permettant d'effectuer des analyses de fixation avec capture d'ions
CA2110050C (fr) Analyses par capture ionique utilisant un membre liant conjugue a de la carboxymethylamylose
WO1995025282A1 (fr) Reactifs de capture d'ions et procedes de realisation de procedes de dosage par fixation
AU626563B2 (en) Ion-capture reagents and methods for performing binding assays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA